Tenpoint Therapeutics Unveils ‘Friends of Presbyopians’ Campaign for Yuvezzi

LONDON and WARREN, N.J.—Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing treatments to improve vision in the aging eye, has announced the launch of “Friends of the Presbyopians,” its first national direct-to-consumer campaign for Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%. The campaign is launching nationwide across digital and social channels, the company advised. Yuvezzi, a dual-agent, once-daily prescription eye drop used for the treatment of presbyopia in adults, received FDA approval in January 2026 and was launched commercially in the U.S. the following March, as reported by VMAIL.